San Diego, Dec. 9, 2011 (Shareholders Foundation) -- An investigation on behalf of investors in shares of Invacare Corporation (NYSE:IVC) over possible Violations of Federal Securities Laws was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Invacare Corporation (NYSE:IVC) concerning whether the company, certain of its officers and directors, or others have possibly violated federal securities laws. Specifically, the investigation concerns whether certain statements regarding Invacares business, its prospects and its operations were potentially materially false and misleading at the time they were made.

Despite that Invacare Corporation reported that its annual Revenue rose from $1.69billion for 09 to $1.72billion in 2010, its Net Income fell from $41.18million for 2009 to $25.34million for 2010. Invacare third quarter Revenue rose from $437.48million last year to $456.52million this year, but its Net Income fell from $15.60million a year earlier to $12.80million for the third quarter in 2011.

Shares of Invacare Corporation (Public, NYSE:IVC) grew from as low as $14.08 per share in the end of 2008 to as high as $34.00 per share in July 2011.

However, since then NYSE IVC stocks declined to $20.58 on December 7, 2011.

Then on December 8, 2011, Invacare Corporation (NYSE: IVC) announced that the U.S. Food and Drug Administration (FDA) has requested that the Company negotiate and agree to a consent decree of injunction relating to previously disclosed inspectional observations at Invacares corporate facility and its wheelchair manufacturing facility in Elyria, Ohio. Invacare Corporation said that the FDA has proposed a consent decree that would require suspension of certain operations at the facilities until they are determined by the FDA to be in compliance.

Following the announcement shares of Invacare (NYSE:IVC) fell on December 8 to $14.68 per share.